Detailed TOC of Global Pharmacogenomics (PGx) Market Insights, Forecast to 2033
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmacogenomics (PGx) Market Size Growth Rate by Type, 2024 VS 2025 VS 2033
1.2.2 Polymerase Chain Reaction (PCR)
1.2.3 Microarray
1.2.4 Sequencing
1.2.5 Other
1.3 Market by Application
1.3.1 Global Pharmacogenomics (PGx) Market Size Growth Rate by Application, 2024 VS 2025 VS 2033
1.3.2 Cardiovascular Diseases (CVD)
1.3.3 Central Nervous System (CNS)
1.3.4 Cancer/Oncology
1.3.5 Infectious Diseases
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Pharmacogenomics (PGx) Market Perspective (2025-2033)
2.2 Pharmacogenomics (PGx) Growth Trends by Region
2.2.1 Pharmacogenomics (PGx) Market Size by Region: 2024 VS 2025 VS 2033
2.2.2 Pharmacogenomics (PGx) Historic Market Size by Region (2025-2033)
2.2.3 Pharmacogenomics (PGx) Forecasted Market Size by Region (2025-2033)
2.3 Pharmacogenomics (PGx) Market Dynamics
2.3.1 Pharmacogenomics (PGx) Industry Trends
2.3.2 Pharmacogenomics (PGx) Market Drivers
2.3.3 Pharmacogenomics (PGx) Market Challenges
2.3.4 Pharmacogenomics (PGx) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmacogenomics (PGx) Players by Revenue
3.1.1 Global Top Pharmacogenomics (PGx) Players by Revenue (2025-2033)
3.1.2 Global Pharmacogenomics (PGx) Revenue Market Share by Players (2025-2033)
3.2 Global Pharmacogenomics (PGx) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pharmacogenomics (PGx) Revenue
3.4 Global Pharmacogenomics (PGx) Market Concentration Ratio
3.4.1 Global Pharmacogenomics (PGx) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmacogenomics (PGx) Revenue in 2025
3.5 Pharmacogenomics (PGx) Key Players Head office and Area Served
3.6 Key Players Pharmacogenomics (PGx) Product Solution and Service
3.7 Date of Enter into Pharmacogenomics (PGx) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmacogenomics (PGx) Breakdown Data by Type
4.1 Global Pharmacogenomics (PGx) Historic Market Size by Type (2025-2033)
4.2 Global Pharmacogenomics (PGx) Forecasted Market Size by Type (2025-2033)
5 Pharmacogenomics (PGx) Breakdown Data by Application
5.1 Global Pharmacogenomics (PGx) Historic Market Size by Application (2025-2033)
5.2 Global Pharmacogenomics (PGx) Forecasted Market Size by Application (2025-2033)
6 North America
6.1 North America Pharmacogenomics (PGx) Market Size (2025-2033)
6.2 North America Pharmacogenomics (PGx) Market Size by Type
6.2.1 North America Pharmacogenomics (PGx) Market Size by Type (2025-2033)
6.2.2 North America Pharmacogenomics (PGx) Market Size by Type (2025-2033)
6.2.3 North America Pharmacogenomics (PGx) Market Share by Type (2025-2033)
6.3 North America Pharmacogenomics (PGx) Market Size by Application
6.3.1 North America Pharmacogenomics (PGx) Market Size by Application (2025-2033)
6.3.2 North America Pharmacogenomics (PGx) Market Size by Application (2025-2033)
6.3.3 North America Pharmacogenomics (PGx) Market Share by Application (2025-2033)
6.4 North America Pharmacogenomics (PGx) Market Size by Country
6.4.1 North America Pharmacogenomics (PGx) Market Size by Country (2025-2033)
6.4.2 North America Pharmacogenomics (PGx) Market Size by Country (2025-2033)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Pharmacogenomics (PGx) Market Size (2025-2033)
7.2 Europe Pharmacogenomics (PGx) Market Size by Type
7.2.1 Europe Pharmacogenomics (PGx) Market Size by Type (2025-2033)
7.2.2 Europe Pharmacogenomics (PGx) Market Size by Type (2025-2033)
7.2.3 Europe Pharmacogenomics (PGx) Market Share by Type (2025-2033)
7.3 Europe Pharmacogenomics (PGx) Market Size by Application
7.3.1 Europe Pharmacogenomics (PGx) Market Size by Application (2025-2033)
7.3.2 Europe Pharmacogenomics (PGx) Market Size by Application (2025-2033)
7.3.3 Europe Pharmacogenomics (PGx) Market Share by Application (2025-2033)
7.4 Europe Pharmacogenomics (PGx) Market Size by Country
7.4.1 Europe Pharmacogenomics (PGx) Market Size by Country (2025-2033)
7.4.2 Europe Pharmacogenomics (PGx) Market Size by Country (2025-2033)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmacogenomics (PGx) Market Size (2025-2033)
8.2 Asia-Pacific Pharmacogenomics (PGx) Market Size by Type
8.2.1 Asia-Pacific Pharmacogenomics (PGx) Market Size by Type (2025-2033)
8.2.2 Asia-Pacific Pharmacogenomics (PGx) Market Size by Type (2025-2033)
8.2.3 Asia-Pacific Pharmacogenomics (PGx) Market Share by Type (2025-2033)
8.3 Asia-Pacific Pharmacogenomics (PGx) Market Size by Application
8.3.1 Asia-Pacific Pharmacogenomics (PGx) Market Size by Application (2025-2033)
8.3.2 Asia-Pacific Pharmacogenomics (PGx) Market Size by Application (2025-2033)
8.3.3 Asia-Pacific Pharmacogenomics (PGx) Market Share by Application (2025-2033)
8.4 Asia-Pacific Pharmacogenomics (PGx) Market Size by Region
8.4.1 Asia-Pacific Pharmacogenomics (PGx) Market Size by Region (2025-2033)
8.4.2 Asia-Pacific Pharmacogenomics (PGx) Market Size by Region (2025-2033)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Pharmacogenomics (PGx) Market Size (2025-2033)
9.2 Latin America Pharmacogenomics (PGx) Market Size by Type
9.2.1 Latin America Pharmacogenomics (PGx) Market Size by Type (2025-2033)
9.2.2 Latin America Pharmacogenomics (PGx) Market Size by Type (2025-2033)
9.2.3 Latin America Pharmacogenomics (PGx) Market Share by Type (2025-2033)
9.3 Latin America Pharmacogenomics (PGx) Market Size by Application
9.3.1 Latin America Pharmacogenomics (PGx) Market Size by Application (2025-2033)
9.3.2 Latin America Pharmacogenomics (PGx) Market Size by Application (2025-2033)
9.3.3 Latin America Pharmacogenomics (PGx) Market Share by Application (2025-2033)
9.4 Latin America Pharmacogenomics (PGx) Market Size by Country
9.4.1 Latin America Pharmacogenomics (PGx) Market Size by Country (2025-2033)
9.4.2 Latin America Pharmacogenomics (PGx) Market Size by Country (2025-2033)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmacogenomics (PGx) Market Size (2025-2033)
10.2 Middle East & Africa Pharmacogenomics (PGx) Market Size by Type
10.2.1 Middle East & Africa Pharmacogenomics (PGx) Market Size by Type (2025-2033)
10.2.2 Middle East & Africa Pharmacogenomics (PGx) Market Size by Type (2025-2033)
10.2.3 Middle East & Africa Pharmacogenomics (PGx) Market Share by Type (2025-2033)
10.3 Middle East & Africa Pharmacogenomics (PGx) Market Size by Application
10.3.1 Middle East & Africa Pharmacogenomics (PGx) Market Size by Application (2025-2033)
10.3.2 Middle East & Africa Pharmacogenomics (PGx) Market Size by Application (2025-2033)
10.3.3 Middle East & Africa Pharmacogenomics (PGx) Market Share by Application (2025-2033)
10.4 Middle East & Africa Pharmacogenomics (PGx) Market Size by Country
10.4.1 Middle East & Africa Pharmacogenomics (PGx) Market Size by Country (2025-2033)
10.4.2 Middle East & Africa Pharmacogenomics (PGx) Market Size by Country (2025-2033)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Details
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Pharmacogenomics (PGx) Introduction
11.1.4 Abbott Laboratories Revenue in Pharmacogenomics (PGx) Business (2025-2033)
11.1.5 Abbott Laboratories Recent Developments
11.2 Affymetrix, Inc.
11.2.1 Affymetrix, Inc. Company Details
11.2.2 Affymetrix, Inc. Business Overview
11.2.3 Affymetrix, Inc. Pharmacogenomics (PGx) Introduction
11.2.4 Affymetrix, Inc. Revenue in Pharmacogenomics (PGx) Business (2025-2033)
11.2.5 Affymetrix, Inc. Recent Developments
11.3 Assurex Health, Inc
11.3.1 Assurex Health, Inc Company Details
11.3.2 Assurex Health, Inc Business Overview
11.3.3 Assurex Health, Inc Pharmacogenomics (PGx) Introduction
11.3.4 Assurex Health, Inc Revenue in Pharmacogenomics (PGx) Business (2025-2033)
11.3.5 Assurex Health, Inc Recent Developments
11.4 Astrazeneca
11.4.1 Astrazeneca Company Details
11.4.2 Astrazeneca Business Overview
11.4.3 Astrazeneca Pharmacogenomics (PGx) Introduction
11.4.4 Astrazeneca Revenue in Pharmacogenomics (PGx) Business (2025-2033)
11.4.5 Astrazeneca Recent Developments
11.5 GeneDX
11.5.1 GeneDX Company Details
11.5.2 GeneDX Business Overview
11.5.3 GeneDX Pharmacogenomics (PGx) Introduction
11.5.4 GeneDX Revenue in Pharmacogenomics (PGx) Business (2025-2033)
11.5.5 GeneDX Recent Developments
11.6 Illumina, Inc.
11.6.1 Illumina, Inc. Company Details
11.6.2 Illumina, Inc. Business Overview
11.6.3 Illumina, Inc. Pharmacogenomics (PGx) Introduction
11.6.4 Illumina, Inc. Revenue in Pharmacogenomics (PGx) Business (2025-2033)
11.6.5 Illumina, Inc. Recent Developments
11.7 Laboratory Corporation of America Holdings
11.7.1 Laboratory Corporation of America Holdings Company Details
11.7.2 Laboratory Corporation of America Holdings Business Overview
11.7.3 Laboratory Corporation of America Holdings Pharmacogenomics (PGx) Introduction
11.7.4 Laboratory Corporation of America Holdings Revenue in Pharmacogenomics (PGx) Business (2025-2033)
11.7.5 Laboratory Corporation of America Holdings Recent Developments
11.8 Myriad Genetics, Inc.
11.8.1 Myriad Genetics, Inc. Company Details
11.8.2 Myriad Genetics, Inc. Business Overview
11.8.3 Myriad Genetics, Inc. Pharmacogenomics (PGx) Introduction
11.8.4 Myriad Genetics, Inc. Revenue in Pharmacogenomics (PGx) Business (2025-2033)
11.8.5 Myriad Genetics, Inc. Recent Developments
11.9 Pathway Genomics
11.9.1 Pathway Genomics Company Details
11.9.2 Pathway Genomics Business Overview
11.9.3 Pathway Genomics Pharmacogenomics (PGx) Introduction
11.9.4 Pathway Genomics Revenue in Pharmacogenomics (PGx) Business (2025-2033)
11.9.5 Pathway Genomics Recent Developments
11.10 Pfizer, Inc
11.10.1 Pfizer, Inc Company Details
11.10.2 Pfizer, Inc Business Overview
11.10.3 Pfizer, Inc Pharmacogenomics (PGx) Introduction
11.10.4 Pfizer, Inc Revenue in Pharmacogenomics (PGx) Business (2025-2033)
11.10.5 Pfizer, Inc Recent Developments
11.11 Qiagen, Inc.
11.11.1 Qiagen, Inc. Company Details
11.11.2 Qiagen, Inc. Business Overview
11.11.3 Qiagen, Inc. Pharmacogenomics (PGx) Introduction
11.11.4 Qiagen, Inc. Revenue in Pharmacogenomics (PGx) Business (2025-2033)
11.11.5 Qiagen, Inc. Recent Developments
11.12 Rocheg
11.12.1 Rocheg Company Details
11.12.2 Rocheg Business Overview
11.12.3 Rocheg Pharmacogenomics (PGx) Introduction
11.12.4 Rocheg Revenue in Pharmacogenomics (PGx) Business (2025-2033)
11.12.5 Rocheg Recent Developments
11.13 Teva Pharmaceutical Industries Ltd.
11.13.1 Teva Pharmaceutical Industries Ltd. Company Details
11.13.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.13.3 Teva Pharmaceutical Industries Ltd. Pharmacogenomics (PGx) Introduction
11.13.4 Teva Pharmaceutical Industries Ltd. Revenue in Pharmacogenomics (PGx) Business (2025-2033)
11.13.5 Teva Pharmaceutical Industries Ltd. Recent Developments
11.14 Thermo Fisher Scientific
11.14.1 Thermo Fisher Scientific Company Details
11.14.2 Thermo Fisher Scientific Business Overview
11.14.3 Thermo Fisher Scientific Pharmacogenomics (PGx) Introduction
11.14.4 Thermo Fisher Scientific Revenue in Pharmacogenomics (PGx) Business (2025-2033)
11.14.5 Thermo Fisher Scientific Recent Developments
11.15 Transgenomic, Inc.
11.15.1 Transgenomic, Inc. Company Details
11.15.2 Transgenomic, Inc. Business Overview
11.15.3 Transgenomic, Inc. Pharmacogenomics (PGx) Introduction
11.15.4 Transgenomic, Inc. Revenue in Pharmacogenomics (PGx) Business (2025-2033)
11.15.5 Transgenomic, Inc. Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
Download FREE Sample Report
